NASDAQ: PRVA · Healthcare Information Services
Privia Health Group (PRVA) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values Privia Health Group (PRVA) at $21.92 a share. The stock last closed at $25.26, which puts the model's fair value 13.2% below the price. On the model's bands that reads as Overvalued.
Revalued . Price is the close of 16 Nov 2026. Privia Health Group, Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $22.19 to $21.92 (-1.2%). The stock's own trading multiple fell with its price, and the fair value follows it in part: most of the move.
What the model makes of itThe price of $25.26 is 13.2% above it: Overvalued, on a medium evidence grade.
What's nextNext report on 25 Feb 2027. Options prices imply a move of about 12% either way over the next month. On the model's Earnings Momentum list since 16 Nov 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give PRVA?
The calibrated range for PRVA over 63 trading days is $22.03 to $29.17. It sits around the last close, and its width comes from the volatility that PRVA's own options imply (42% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $18.57 to $25.97. In 28% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Privia Health Group, Inc. functions as a national entity focused on empowering physicians throughout the United States. It is classed under Healthcare Information Services.
Faircurve's model put the fair value at $21.92 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $22.19, so the model's fair value moved -1.2%. In the model's own words, the stock's own trading multiple fell with its price, and the fair value follows it in part: most of the move. The calibrated range over 63 trading days is $22.03 to $29.17, built from the volatility the stock's own options imply. The range was calibrated weekly against realised prices, using 8,038 past valuations refreshed on 14 Nov 2026. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence Medium, based on how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. The grade does not say whether the fair value is right.
On quality, the model gives the company an overall score of 70 out of 100 against comparable companies. The factors that stand out most are Balance sheet at 100, with net debt to EBITDA of -5.88x against a peer median of 4.74x, Earnings quality at 82, with FCF to net income of 3.11x, and Growth quality at 80, with trailing revenue growth of 22.3% against a peer median of 20.2%. The model compares the company with Waystar Holding Corp. (WAY), Certara, Inc. (CERT), Doximity, Inc. (DOCS), Omnicell, Inc. (OMCL) and HealthStream, Inc. (HSTM).
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does PRVA report earnings, and how has the stock reacted?
Privia Health Group's next earnings report is scheduled for 25 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 9.7% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. PRVA's 30 day implied volatility works out to about 12.0% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across PRVA's last 8 reports, ignoring direction, was 4.5%.
How does PRVA score on business quality?
Privia Health Group's overall quality score is 70 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 57 | 7.6%ROIC | -4.7% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 82 | 3.11xFCF / net income | |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 80 | 22.3%Revenue growth, trailing | 20.2% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 68 | 0.0%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 100 | -5.88xNet debt / EBITDA | 4.74x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 35 | 8.5 ptsEBITDA margin downside volatility, 5y | 7.0 pts |
How does PRVA compare with similar companies?
The companies in healthcare information services closest to Privia Health Group in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| WAY Waystar Holding Corp. | $28.11 | $30.05 | +6.9% | Fairly valued |
| CERT Certara, Inc. | $11.39 | $11.49 | +0.9% | Fairly valued |
| DOCS Doximity, Inc. | $32.77 | $32.13 | -2.0% | Fairly valued |
| OMCL Omnicell, Inc. | $35.44 | $37.58 | +6.0% | Fairly valued |
| HQY HealthEquity, Inc. | $104.58 | $104.84 | +0.2% | Low evidence grade |
| HSTM HealthStream, Inc. | $27.68 | $27.45 | -0.8% | Fairly valued |
| BTSG BrightSpring Health Services, Inc. Common Stock | $71.37 | $68.74 | -3.7% | Low evidence grade |
What the comparable companies' multiples alone would give for PRVA, the peer-implied price, is $13.77 a share on this run. The fair value weighs that against the company's own multiple.
All healthcare information services stocks ranked by gap to fair value
Privia Health Group at a glance
Privia Health Group, Inc. functions as a national entity focused on empowering physicians throughout the United States.
- Market value
- $3.1B
- Sector
- Healthcare
- Industry
- Healthcare Information Services
- Revenue expected, next twelve months
- $2.7B
- Consensus revenue growth, next fiscal year
- +18.6%
- Analysts with estimates
- 9
- Beta to the US market
- 0.20
- First valued by Faircurve
- 11 Jul 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. PRVA was not among them.
How the fair value is worked out: the model prices Privia Health Group on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for PRVA was $22.19. As of 14 Nov 2026 it is $21.92, a change of -1.2%. The stock's own trading multiple fell with its price, and the fair value follows it in part: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Privia Health Group's valuation
Is Privia Health Group stock undervalued or overvalued?
On Faircurve's model, PRVA reads as Overvalued as of 14 Nov 2026. The model's fair value is $21.92 a share against a last close of $25.26, a gap of -13.2%.
What is PRVA's fair value?
$21.92 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $18.57 to $25.97.
What price range does the model give PRVA?
$22.03 to $29.17 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Privia Health Group report earnings next?
The next report is scheduled for 25 Feb 2027. Companies can move their dates.
How much has PRVA moved on past earnings reports?
Across its last 8 reports the median two session move was 4.5%, ignoring direction. The largest was +9.0% around the report of 5 Nov 2026.
How confident is the model in this valuation?
The model's evidence grade for PRVA is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on PRVA
The model has an idea open on PRVA under Earnings Momentum since 16 Nov 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on PRVA with their outcomes. A free account is enough.